Endexo® surface modifying macromolecules enhance the biocompatibility of medical devices that come in contact with blood, tissue, or other biological fluids. They are low molecular weight fluoro-oligomeric additives that migrate to the top few nanometers of the device surface during the manufacturing process.
In the presence of blood, the modified surfaces are able to suppress procoagulant protein conformation, reduce platelet adhesion and inhibit platelet activation. In the presence of bacteria mediated fluids the modified surfaces are effective at reducing bacteria adhesion (up to 5 log CFU) and encrustation. Endexo® modified devices reduce thrombosis, infection and biofouling all without the use of drugs.
Endexo® platform technology can be applied to a variety of base polymers (e.g. polyurethane, polysulfone, PVC, polypropylene, and silicone) and manufacturing techniques (e.g. extrusion, solution spinning, and injection molding). Endexo® molecules become an integral part of the base material providing durable surface modification and extended efficacy compared to traditional coatings.
Average reduction across 8500 BioFlo PICCs studied:
As reported by AngioDynamics
Blood Contacting Devices
Non-dialysis blood lines
Medical Device Anti-fouling
Urinary catheters and stents
Sensors and diagnostics